Background

The available burden of disease (BoD) studies in pneumococcal disease in Spain are limited to analyzing data restricted to specific geographical regions. This study assessed the clinical burden associated with streptococcus pneumoniae in Spain.

Methods

A retrospective study was conducted using Conjunto Mínimo de Datos-Hospitalización (CMBD-H), a publicly available database provided by the Spanish Ministry of Health covering approximately 90% of hospitalization episodes.

The study population consisted of individuals aged 15 years and older who were hospitalized with a diagnosis of pneumonia, bacteremia and meningitis due to Streptococcus Pneumoniae in 2015.

Results

In 2015, the estimated burden of pneumococcal disease potentially avoidable through vaccination represented 10,274 inpatient admissions including 9,015 cases of pneumonia, 309 cases of meningitis and 950 cases of septicemia. Additionally, 867 deaths were registered during these hospitalization episodes. The information available in CMBD-H only captures individual hospitalization episodes and cannot capture per patient hospitalization, therefore it could be used as an approximation to estimate disease incidence, but not real incidence, which is a limitation of the study.

Conclusions

Pneumococcal disease still contributes to substantial morbidity and mortality among individuals aged 15 years and older in Spain.

Background

Anti-pneumococcal vaccines are the most effective strategy to prevent pneumococcal disease. However, the pneumococcal burden continues to be a remarkable problem worldwide. Thus, new conjugated vaccines are under development. Through the analysis of the prevalence of pneumococcal serotypes between 2005-2019, we aim to determine the theorical effect of these vaccines in Bogotá, Colombia.

Methods

This is a retrospective analysis of patients reported to a surveillance program due to invasive pneumococcal disease, between 2005 and 2019. We compared the potential serotype coverage of PCV10, PCV13, PCV15, PCV20 by age groups to determine the possible role of these vaccines in Bogotá, Colombia.

Results

A total of 2605 patients were included. In the group of children ˂5 years, PCV10 had serotype coverage of 9%, PCV13 of 27.8%, PCV15 of 28.2%, and PCV20 of 30%. In Adults ˃18 years, PCV10 covered was 11.8%, PCV13 of 26.6%, PCV15 of 27.7%, and PCV20 of 32.7% (Figure-1). Additionally, in adults ˃65 years, PCV10 covered was 10.2%, PCV13 of 26%, PCV15 of 27.4%, and PCV20 of 34%.

Conclusions

According to the most prevalent serotypes in our city, the usage of new vaccines may prevent some episodes of IPD in Bogotá, Colombia. However, further clinical, epidemiological and pharmacoeconomical studies should be performed

Background

Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide, being the most common etiological pathogen of pneumonia, meningitis and bacteremia. This study assessed the healthcare resource utilization and costs associated with inpatient admissions for pneumonia and invasive pneumococcal disease (IPD) in individuals aged 15 years and older in Spain during 2015.

Methods

A retrospective, descriptive study was conducted using Conjunto Mínimo de Datos-Hospitalización (CMBD-H), a publicly available database provided by the Spanish Ministry of Health capturing approximately 90% of hospitalization episodes.

The economic burden of pneumococcal disease was calculated by multiplying the average cost associated with an inpatient admission for pneumonia or IPD by the number of each type of episode. Additionally, the length of stay (days of hospitalization) due to pneumococcal disease was estimated

Results

The aggregated annual economic burden of pneumococcal disease was 54.1 million euros ($60.1 million) These represented over 97,390 hospitalization days, 80% of which were associated with pneumococcal pneumonia. Pneumococcal meningitis has the highest average cost per episode, 10,706 euros ($11,904) followed by the average cost of a septicemia episode, 9,338 euros ($10,382).

Conclusions

These results demonstrate the substantial economic impact of pneumococcal disease on the Spanish National Health System.

Background

Incidence of Invasive pneumococcal disease (IPD) depends on numerous factors, including vaccine undertake, geographic location, and serotype prevalence. There is limited data about the incidence of Streptococcus pneumoniae (Spn), serotype distribution, and clinical characteristics of adults hospitalized due to IPD in Colombia. Thus, this study will attempt to bridge this gap in the literature.

Methods

This is an observational, retrospective, citywide study conducted between 2012 and 2019 in Bogotá, Colombia. We analyzed, reported positive cases of IPD. Importantly, Bogotá represents approximately 75% of the Colombian population. Strains were isolated in each hospital and typified in a centralized laboratory. The objectives included assessment of Spn serotype distribution, clinical diagnosis, mortality, ICU admission, and need for mechanical ventilation.

Results

A total of 314 patients with IPD were included, 54.8% male. The leading cause of IPD was pneumonia (33%), followed by meningitis and sepsis. The most prevalent serotypes were 19A (13.1%) and 3 (12.4%). The overall hospital mortality was 30%. Moreover, 65.6% were admitted to the ICU, 44.9% required invasive mechanical ventilation, and 5.1% non- invasive mechanical ventilation.

Conclusions

Pneumococcal pneumonia continues to be the most prevalent cause of IPD. Serotypes 19A and 3 are the leading cause of IPD in Colombian adults.